Research console / 05
Tesamorelin liver fat (NAFLD / MASLD) in the research literature
The hepatic-fat endpoint, read trial by trial — what moved, by how much, and in whom.
The short version
This page reads the tesamorelin liver fat record — liver fat being fat that builds up inside the liver, called NAFLD or, in newer terms, MASLD (metabolic dysfunction-associated steatotic liver disease). In trials of people living with HIV, tesamorelin lowered the amount of fat in the liver, sometimes pushing it back into the normal range. The leading explanation is indirect: by shrinking the deep visceral fat that drives liver-fat buildup, the liver clears too. As with everything here, the strong data are in HIV cohorts, and liver use outside that setting is off-label and still under study.
What the hepatic-fat trials measured
The tesamorelin liver fat record is built on imaging endpoints. In a JAMA trial of antiretroviral-treated adults (n=50), tesamorelin reduced the hepatic lipid-to-water percentage by a net 2.9% versus placebo (P=0.003) [6]. A 12-month Lancet HIV trial (n=61) in patients with NAFLD cut hepatic fat fraction by 37% relative to placebo (P=0.016), and 35% of tesamorelin recipients versus 4% on placebo reached a hepatic fat fraction below 5% — the threshold generally considered normal (P=0.0069); the authors noted further study of liver histology is needed [7].
The newest panels confirm the effect in the modern treatment era. The 2024 integrase-inhibitor-era trial reported hepatic fat down 4.2% versus -0.5% on placebo (P=0.01) over 12 months [9], and the 2026 meta-analysis of five trials pooled a mean hepatic-fat-fraction reduction of 4.28% (P<0.001) [8]. We index these as the NAFLD / MASLD research findings.
Why visceral fat is the proposed mediator
MASLD in people living with HIV follows a more aggressive course than in HIV-negative individuals, and reviews list tesamorelin among promising HIV-specific therapies [13]. A review of hepatic fibrosis in people living with HIV identifies visceral fat as a major risk factor and lists tesamorelin among the promising therapy options [14]. The mechanistic story is consistent across the record: tesamorelin's primary action is on visceral fat, and the hepatic benefit is best explained as a downstream consequence of reducing the deep abdominal fat that drives fatty-liver progression [6][8].
Why HIV-specific liver disease drew the research
The hepatic interest in tesamorelin is rooted in a specific clinical problem. A 2025 review notes that MASLD in people with HIV runs a more aggressive course than in HIV-negative individuals, and that dedicated studies of the growth hormone-releasing hormone analogue tesamorelin have shown promise specifically in MASLD-HIV [13]. Hepatic fibrosis — scarring that follows sustained fat and inflammation — is both more prevalent and faster-progressing in this population, with visceral adiposity a major driver [14].
That is why the liver-fat trials were run where they were: in HIV cohorts with measurable hepatic fat, where the unmet need was greatest and the mechanism most relevant [7][9]. The mechanistic rationale extends to the gene level — growth-hormone-axis stimulation has been associated with upregulated hepatic oxidative-phosphorylation gene sets and downregulated inflammatory signaling, a proposed basis for the steatosis benefit beyond simple fat redistribution [6].
Imaging fat versus liver disease
An important boundary runs through this evidence. The trials measured hepatic fat by imaging — MRI-based hepatic fat fraction and lipid-to-water percentage — and tesamorelin moved those numbers consistently [6][7][9]. But the authors of the Lancet HIV NAFLD trial were explicit that further study of liver histology is needed: a drop in imaged fat is not the same as biopsy-confirmed resolution of fibrosis or steatohepatitis [7].
So the honest read of the NAFLD / MASLD research findings is precise. Tesamorelin reliably lowers liver fat on imaging in HIV cohorts, sometimes back below the 5% normal threshold [7]; whether that translates to durable improvement in liver structure over years remains an open question the literature itself flags [7][13]. As with the visceral-fat effect, the benefit is studied within continued dosing and within an HIV-positive population — not as a general fatty-liver treatment [9].
Can tesamorelin reduce liver fat?
In a JAMA trial of antiretroviral-treated HIV adults, tesamorelin reduced hepatic lipid by a net 2.9% versus placebo [6]; a 2024 integrase-inhibitor-era trial showed -4.2% versus -0.5% [9]; and a 2019 Lancet HIV trial cut hepatic fat fraction 37% relative to placebo [7]. These are findings in HIV cohorts.
Is tesamorelin being studied for fatty liver disease?
A 12-month Lancet HIV trial in HIV patients with NAFLD reduced hepatic fat fraction by 37% relative to placebo, and 35% versus 4% reached a hepatic fat fraction below 5% [7]. The authors noted that further study of liver histology is needed — imaging fat is not the same as biopsy-confirmed disease resolution.
How does tesamorelin affect the liver?
Beyond lowering hepatic fat, MASLD in HIV follows a more aggressive course, and reviews list tesamorelin among promising HIV-specific therapies [13][14]. Visceral-fat reduction is the proposed mediator of the hepatic benefit — the liver clears as the deep abdominal fat that drives it shrinks [6][8].